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Introduction
Polycythaemia vera (PV) is a rare haematologic disorder
characterised by clonal proliferation of bone marrow prog-
enitors, leading to abnormal production of the erythroid cell
line that is independent of physiological growth factor ery-
thropoietin (EPO). This led investigators to search down-
stream receptor events, and therefore the pathophysiology
of this disease has advanced considerably with the recent
discovery of an acquired mutation of JAK2 (V617F) in the
vast majority of PV patients, and in almost half of those
with essential thrombocythaemia (ET) and idiopathic
myelofibrosis (IMF) [1].
Earlier studies in untreated patients found a high inci-
dence of thrombotic events and a life expectancy of about
18 months after diagnosis. Cytoreductive treatments of
blood hyperviscosity by phlebotomy or chemotherapy have
been shown to dramatically reduce the number of thrombot-
ic events, even though haematological transformations
towards IMF and acute leukaemia (AL) still represent a
major cause of death [2].
Current recommendations for management of PV are
based on a limited number of randomised clinical trials
(RCTs), and a series of prospective and retrospective stud-
ies that have evaluated the effect of different treatments on
the main outcomes of the disease, such as thrombotic com-
plications, haematological evolution into AL or myelofibro-
sis and survival. The first studies were pioneered by the
Polycythemia Vera Study Group (PVSG), and their results
still have a significant impact on patient management [3, 4].
Recently, a prospective study called the European
Collaboration on Low-dose Aspirin in Polycythemia
(ECLAP) evaluated the current epidemiology of PV in
Europe [5]. The strength of this survey is the huge number
of patients included, and the assessment of events that are
externally validated, as usually required for clinical trials.
In this article, we have reviewed PVSG and ECLAP stud-
ies with the aim to formulate updated guidelines for risk strat-
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Abstract  The clinical course of polycythaemia vera is
marked by a high incidence of thrombotic complications,
which represent the main cause of morbidity and mortality.
Major predictors of vascular events are increasing age and
previous thrombosis. Myelosuppressive drugs can reduce
the rate of thrombosis, but there is concern that their use
raises the risk of transformation into acute leukaemia. To
tackle this dilemma, a risk-oriented management strategy is
recommended. Low-risk patients should be treated with
phlebotomy and low-dose aspirin. Cytotoxic therapy is
indicated in high-risk patients, with the drug of choice
being hydroxyurea because its leukaemogenicity is low.
The recent discovery of JAK2 V617F mutation in the vast
majority of polycythaemia vera patients opens new avenues
for the treatment of this disease. Novel therapeutic options
theoretically devoid of leukaemic risk, such as alpha-inter-
feron and imatinib, affect JAK2 expression in some
patients. Nevertheless, these drugs require further clinical
experience and, for the time being, should be reserved for
selected cases.
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ification and patients’ management. In addition, given the
recent discovery of JAK2 mutation in most PV patients, we
tackle the question of how these molecular advances may
affect current treatment approaches and future clinical trials.
Classical studies
In the first study by the PVSG (01 trial) [3], 431 patients
were randomised to one of the following treatments: (a)
phlebotomy alone; (b) radiophosphorus (32P) therapy plus
phlebotomy or (c) chlorambucil plus phlebotomy. Patients
treated with phlebotomy alone have a better median survival
time (13.9 years) than those receiving 32P (11.8 years) or
chlorambucil (8.9 years). Causes of death are different in the
3 groups. Phlebotomised patients show an excess of mortal-
ity within the first 2–4 years, principally caused by throm-
botic complications. Those patients in the two myelosup-
pression arms suffer higher rates of AL and other malignan-
cies developing later during the follow-up. The incidence of
IMF was virtually identical in the three arms.
In the late 1970s, the search for a nonmutagenic myelo-
suppressive agent led the PVSG to investigate hydroxyurea
(HU), an antimetabolite that prevents DNA synthesis by
inhibiting the enzyme ribonucleoside reductase. At that
time, it was assumed that this agent would not be leukae-
mogenic or carcinogenic. In the last PVSG report [4], 51 PV
patients treated with HU were followed for a median and
maximum of 8.6 and 15.3 years, respectively. The incidence
of AL, myelofibrosis and death were compared with the
incidence in 134 patients treated only with phlebotomy in
the PVSG-01 protocol. There are no significant differences
in any of the 3 parameters, although the HU group shows a
tendency to more ALs (9.8% vs. 3.7%), less myelofibrosis
(7.8% vs. 12.7%) and fewer total deaths (39.2% vs. 55.2%).
Based on these studies, the PVSG produces the following
recommendations that are shared by experts in the field [2, 3]:
phlebotomy is suggested in all patients to keep the haemat-
ocrit (HCT) below 0.45. Stable patients at low risk for throm-
bosis (age <60 years, no history of thrombosis) may not
require additional therapy. In patients at high risk for throm-
bosis, or with a very high phlebotomy requirement, the choice
of a myelosuppressive agent is age-adapted. Older patients
can be managed with 32P, busulfan or pipobroman, whereas
HU is considered the agent of choice in younger patients. 
In a small size RCT, the PVSG evaluated the role of
aspirin in PV [6]. A group of 166 patients was randomly
assigned to the combination of high-dose aspirin (900 mg
daily) plus phlebotomy and dipyridamole vs. 32P. The trial
was stopped because of excessive major bleeding without
demonstration of efficacy in thrombosis prevention. This
study has a significant impact on clinical practice: in a
recent survey among American physicians it is reported that
the use of aspirin is reserved to a minority of PV patients
due to a concern for safety [7].
“The ECLAP papers”
General design
The ECLAP study includes a network of 94 haematological
centres from 12 countries and an international coordinating
centre in Italy (Consorzio Mario Negri Sud). Overall, 1638
PV patients were included in the study [5]. Five hundred
and eighteen (32%) of these patients are entered into a par-
allel, double-blind, placebo-controlled, randomised clinical
trial aimed at assessing the efficacy and safety of low-dose
aspirin [8]. The remaining 1120 (68%) are registered in an
observational, prospective, cohort study. The main reasons
for excluding the patients from the randomised trial were:
need for antithrombotic therapy (66%), contraindication to
ASA (24%) or patients’ unwillingness (18%).
Diagnosis of PV was based upon the criteria established
by the PVSG [3] and patients were asked to adhere to the
treatment recommended by the haematologist in charge of
their care. The procedures in the study were planned to
mimic the routine care of patients with PV. Data collection
was specifically recorded at follow-up visits at 12, 24, 36,
48 and 60 months respectively. The mean duration of fol-
low-up was 2.7 years (0–5.3).
The main outcome measures were fatality, and major
and minor thrombosis. Major thrombosis includes cerebral
ischaemic stroke, myocardial infarction, peripheral arterial
thrombosis and venous thromboembolism. All fatal and
major events were objectively documented and validated by
an ad hoc committee of expert clinicians blinded to patients’
treatment assignment. Haematological evolution to myelofi-
brosis or AL, and overall mortality were also evaluated.
Standard statistical methods were used for analysis.
Clinical course of patients
Thirty-five percent of the 1638 enrolled patients had been
newly diagnosed or diagnosed in the two years before reg-
istration, whereas in 27% and 38% of cases the diagnosis of
PV had been made between 2 and 5 years and more than 5
years prior to registration respectively. Median age at diag-
nosis and at registration was 60 and 65 years respectively.
Thrombotic events before registration were documented in
633 (38.4%) cases. The median duration of follow-up from
registration was 2.8 years (range 0–5.3), and the median
time elapsed from diagnosis was 6.3 years (range 1–18).
Overall mortality during follow-up was 3.5 deaths/100 per-
sons per year. As compared with the general Italian popula-
tion standardised for age and sex, the excess in mortality of
PV patients is 2.1 times. Cardiovascular events, haemato-
logical transformation (mainly AL) and major bleeding are
responsible for 41%, 13% and 4% of deaths, respectively.
During follow-up, nonfatal major thromboses were
observed in 122 patients (7.4%), of which 87 were arteri-al (53 cerebral ischaemia, 14 acute myocardial infarction
and 20 peripheral arterial thrombosis) and 50 (3%)
venous. Progression to MF occurred in 38 patients (2.3%),
with an incidence rate of approximately 1% patient-year.
Transformation to AL during 2.7 years follow-up was reg-
istered in 22 cases (1.3%) with a median time lapse from
diagnosis of 6.3 years [5].
Risk stratification
In the ECLAP study, the incidence of cardiovascular com-
plications is higher in patients aged more than 65 years
(5.0% patient-year, hazard ratio 2.0, 95% confidence inter-
val [CI] 1.22–3.29, p<0.006), or with a history of thrombo-
sis (4.93% patient-year, hazard ratio 1.96, 95% CI
1.29–2.97, p=0.0017) than in younger subjects with no his-
tory of thrombosis (2.5% patient-year, reference category).
Patients with both a history of thrombosis and age more
than 65 years have the highest risk of cardiovascular events
during follow-up (10.9% patient-year, hazard ratio 4.35,
95% CI 2.95–6.41, p<0.0001) [5]. These data confirm pre-
vious findings that increasing age and a history of thrombo-
sis are the two most important prognostic factors for the
development of vascular complications [3]. Other signifi-
cant predictors of survival and cardiovascular morbidity are
smoking, diabetes mellitus and congestive heart failure.
Therefore, patients with PV should be stratified into a dif-
ferent risk category on the basis of their probability of devel-
oping thrombotic complications. Young age and no prior
thrombosis define a low-risk category, whereas age above 65
years or prior thrombosis define a “high-risk” category. This
classification forms the rationale for a risk-adapted therapy [2].
The aspirin trial
The efficacy and safety of low-dose aspirin (100 mg daily)
has been formally assessed in a nested double-blind, place-
bo-controlled, randomised clinical trial carried out in the
frame of the ECLAP project [8]. Five hundred and eighteen
patients (32% of the total ECLAP study population) with-
out a clear indication or contraindication to aspirin were
enrolled. Median age at recruitment was 61 years and 59%
of patients were men. Previous cardiovascular events were
reported in only 10% of cases, so that this trial included
mainly an asymptomatic, low-risk population. Median fol-
low-up was 2.8 years. Aspirin significantly lowered the risk
of a primary combined end-point including cardiovascular
death, nonfatal myocardial infarction, nonfatal stroke and
major venous thromboembolism (relative risk 0.4 [95% CI
0.18–0.91], p=0.0277). Total and cardiovascular mortality
were also reduced by 46% and 59%, respectively. Major
bleeding episodes were only slightly increased by aspirin
(relative risk 1.6, 95% CI 0.27–9.71). Thus, the results of
this trial eliminate the concern raised by the PVSG about
the benefit/risk ratio of aspirin in PV.
In other studies, aspirin at different doses (30–500
mg/day) was found to control microvascular symptoms,
such as erythromelalgia, and transient neurological and ocu-
lar disturbances including dysarthria, hemiparesis, scintillat-
ing scotomas, amaurosis fugax, migraine and seizures [9].
Current treatment recommendations (Fig. 1)
Based on the PVSG seminal RCT [3], phlebotomy is recom-
mended in all patients with PV, and should represent the only
cytoreductive treatment in patients at low risk for vascular
complications. The target HCT of 0.45 in men and 0.42 in
women was suggested by this study group, although not sup-
ported by solid data. This recommendation is made by
Pearson and Wetherley-Mein [10], who showed in univariate
analysis a correlation between thrombosis and HCT when this
is greater than 45%. In the ECLAP study, despite the recom-
mendation of maintaining the HCT values at less than 45%,
only 48% of patients have HCT values below this threshold,
while 39% and 13% have values between 45% and 50% and
greater than 50% respectively. Thus, an appropriate controlled
study to establish the real HCT target in PV is needed.
Given the results of the ECLAP trial [8], low-dose
aspirin (100 mg daily) is recommended in all PV patients
without history of major bleeding, gastric intolerance or
extreme values of thrombocytosis. However, a recent study
shows that previous gastrointestinal bleeding is not an
absolute contraindication to the prophylactic use of aspirin,
Fig. 1 Flow-chart of recommended treatment for patients with
polycythaemia vera (PV)
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as the use of proton pump inhibitors may overcome the risk
of gastric bleeding due to aspirin [11].
Hydroxyurea
HU is highly effective in patients with myeloproliferative dis-
orders at high risk of thrombosis, and should be considered as
first-line therapy; however, concerns regarding its leukae-
mogenic potential should be carefully considered [12–14].
To date there are no randomised studies powered to assess
the relative risk of malignant transformation in myeloprolifer-
ative disease (MPD) patients given HU. These disorders have
an inherent tendency to evolve into AL, even in the absence of
specific therapy. Thus, studies that enrolled patients in need of
therapy automatically selected patients with more active dis-
ease and a higher propensity to malignant transformation.
Furthermore, leukaemic transformation occurs after a lead
time of several years, and only long-term studies with a large
number of patients are suitable to assess this issue [15].
The 1638 patients prospectively enrolled in the ECLAP
study, with a median disease duration of 6.3 years, represent
an appropriate population to reach this goal. In a recent analy-
sis of the leukaemogenic risk in these patients,HU alone does
not enhance the risk of leukaemia in comparison with patients
treated with phlebotomy only (hazard ratio 0.86, 95% CI
0.26–2.88; p=0.8) [16]. Over the same time frame, the risk is
significantly increased by exposure to radiophosphorus,
busulphan or pipobroman (hazard ratio 5.46, 95% CI
1.84–16.25;  p=0.002). The use of HU in patients already
treated with alkylating agents or radiophosphorus also
enhances the leukaemic risk (hazard ratio 7.58, 95% CI
1.85–31; p=0.0048,) and this is seen also in ET [16, 17].
Thus, the bulk of evidence does not support a leukae-
mogenic risk for HU, but the debate on whether AL is part of
the natural history of PV or is a consequence of therapy is still
matter of discussion. It is wise to adopt a cautionary princi-
ple, and to consider carefully the use of this agent in young
subjects and in those previously treated with other myelosup-
pressive agents or carrying cytogenetic abnormalities.
Interferon alpha (IFN-a)
The use of IFN-α in PV was pioneered by Silver [18].
IFN-α suppresses the proliferation of haematopoietic
progenitors, has a direct inhibiting effect on bone marrow
fibroblast progenitor cells and antagonises the action of
platelet-derived growth factor, transforming growth factor-
beta and other cytokines, which may be involved in the
development of myelofibrosis [19].
Published reports concern small consecutive series of
patients in whom haematological response and side effects
were evaluated. One review analyses the cumulative expe-
rience with IFN-α in 279 patients from 16 studies [20].
Overall responses are 50% for reduction of HCT to less
than 0.45% without concomitant phlebotomies, 77% for
reduction in spleen size and 75% for reduction of pruritus.
Results from single-institution studies with long-term fol-
low-up are similar [21, 22].
In a recent review article, Silver updates his experience
on the long-term use (median 13 years) of IFN-α in 55
patients with PV [23]. Complete responses, defined by phle-
botomy free, HCT less than 45% and platelet number below
600 000/ml, are reached in the great majority of cases after
1–2 years of treatment, and the maintenance dose can be
decreased in half of the patients. Noteworthy is the absence
of thrombohaemorrhagic events during this long follow-up.
The main problem with IFN-α therapy, apart from its
costs and parenteral route of administration, is the incidence
of side effects. Fever and flu-like symptoms are experienced
by most patients and usually require treatment with paraceta-
mol. Signs of chronic IFN-α toxicity, such as weakness,
myalgia, weight and hair loss, severe depression, and gas-
trointestinal and cardiovascular symptoms, make it necessary
to discontinue the drug in about one third of patients [20].
Overall, the role of IFN-α in PV therapy requires controlled
clinical trials evaluating long-term clinical end-points.
The JAK2 mutation and future clinical trials
The recent description of a point mutation (V617F) in the
JAK2 kinase of a large proportion of patients with MPD has
fundamentally changed our understanding of the molecular
aetiology of the disorders [24–30]. This change is observed in
70%–95% of PV patients, as well as in 50%–70% of ET and
35%–50% of IMF patients. The large variation in the report-
ed frequencies is most likely due to both technical differences
in allele detection (DNA sequencing vs. allele-specific PCR)
and to relatively small sample size. The majority of patients
carry a heterozygous mutation, retaining one wild type JAK2
allele. About 30% of patients, however, have experienced
mitotic recombination and loss of heterozygosity at chromo-
some 9p, leading to duplications of the mutant JAK2 allele.
Hence these patients are homozygous for the mutation. The
mutation at amino acid 617 is located in the JH2 pseudo-
kinase domain, and renders the enzyme constitutively active.
In cell culture and mouse models, transduction of Jak2V617F
leads to cytokine hypersensitivity and erythrocytosis. These
data demonstrate that this mutation plays a pivotal role in
causing the PV phenotype, and generates great interest in
determining if patients are sensitive to small molecular
agents specific to the pseudokinase domain of JAK2.
Clinical trials are currently exploring whether Imatinib
may have a role in PV. Therapy with this inhibitor of sever-
al protein-tyrosine kinases, including ABL, PDGFR, KIT
and FMS tyrosine kinase, has been proposed. Silver et al.
report responses in 13 of 23 (57%) PV patients at doses upto 800 mg day [31]. Effects are predominantly on erythroid
progenitors with decrease in spleen size and elimination of
need for phlebotomy. Control of thrombocytosis is less
effective, necessitating additional therapy in some patients.
The relation of Imatinib treatment and JAK2 mutation is
explored by Jones et al. in 9 PV patients for whom pre-treat-
ment samples were available [32]. There are two cases that
achieved complete haematologic remission and a 2–3-fold
reduction in the percentage of V617F alleles. According to
these authors, the observed clinical benefit may be a conse-
quence of KIT rather than JAK2 inhibition.
The same authors report that therapy with IFN-α (1 MU
3 times weekly to 3 MU daily) in 7 PV patients induces a
lower percentage of V617F alleles compared to a control
group of patients treated by phlebotomy and HU [32].
Recently, in a multicentre phase II trial of Peg-IFN-α2a in 27
PV patients, Kiladjian et al. show a decrease of JAK2 mutant
expression in 24 cases (89%). In one patient mutant JAK2
was no longer detectable after 12 months of therapy [33].
The recently established MPD Research Consortium
(MPD-RC) is going to test the hypothesis of therapeutic
intervention with these novel agents in controlled ran-
domised phase III clinical trials enrolling high risk patients
with PV. The aim is to compare changes in key biomarkers
including JAK2 mutation with specific clinical end-points.
Conclusions
RCTs from PVSG and from ECLAP provide evidence-
based guidelines for the management of patients with PV.
New clinical trials should be aimed at reducing fatal and
nonfatal events of our patients, and ought to be planned
according to the added benefit that could be expected from
new study intervention as compared to standard treatment. It
is likely that the new discoveries of biomarkers and genetic
abnormalities in MPD will allow the substitution of clinical
with nonclinical end-points. As PV is a relatively rare dis-
ease, and the related complications evolve over several
years, future trials including surrogate end-points and
specifically JAK2 mutation will be welcome.
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